Global R&D Pipeline
My Favorite
Hot Targets:
CDH17
Back
Total number of drugs
60
Phase II and later clinical stages
0%
Involving companies
83
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMD-2816 | IMD-2816 | Drug conjugates | Neoplasms | CD3 stimulants CDH17 modulators | Shanghai Affinity Biopharmaceutical Co., Ltd. | Shanghai Affinity Biopharmaceutical Co., Ltd. | IND Application | IND Application | - | - | - | - | - | - | - | - | IMD-2816 | - | - | detail > | |
| HDM-2017 | HDM-2017 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders | CDH17 antagonists | Huadong Medicine Co., Ltd. | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Huadong Medicine Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | HDM-2017 | - | - | detail > | |
| BI-905711 | BI-905711 | Bispecific antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Other Diseases | CDH17 antagonists DR5 agonists | Boehringer Ingelheim GmbH | Boehringer Ingelheim GmbH Boehringer Ingelheim RCV GmbH & Co. KG Memorial Sloan Kettering Cancer Center Nippon Boehringer Ingelheim Co., Ltd. The University of Texas MD Anderson Cancer Center Boehringer Ingelheim Corp. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | BI-905711 | - | - | detail > | |
| HS-20110 | HS-20110 | Antibody drug conjugate (ADC) | Neoplasms | CDH17 modulators | Shanghai Hansoh Biomedical Co. Ltd. | Changzhou Hansoh Pharmaceutical Co., Ltd. Shanghai Hansoh Biomedical Co. Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | HS-20110 | - | - | detail > | |
| Anti-CDH17 CAR-T Cell(Guangzhou Bio-gene Technology) | Anti-CDH17 CAR-T Cell(Guangzhou Bio-gene Technology) | CAR-T | Neoplasms | CDH17 modulators | Guangzhou Bio-gene Technology Co., Ltd. | Guangzhou Bio-gene Technology Co., Ltd. | Early Phase 1 | Early Phase 1 | - | - | - | - | - | - | - | - | Anti-CDH17 CAR-T Cell(Guangzhou Bio-gene Technology) | - | - | detail > | |
| CDH17/GUCY2C CAR-T(Guangzhou Bio-gene Technology) | CDH17/GUCY2C CAR-T(Guangzhou Bio-gene Technology) | CAR-T | Neoplasms Digestive System Disorders | CDH17 modulators GC-C modulators | Guangzhou Bio-gene Technology Co., Ltd. | Guangzhou Bio-gene Technology Co., Ltd. | Clinical | Clinical | - | - | - | - | - | - | - | - | CDH17/GUCY2C CAR-T(Guangzhou Bio-gene Technology) | - | - | detail > | |
| ARR-217 | ARR-217 | - | - | - | - | - | - | ARR-217 | - | - | detail > | ||||||||||
| MRG007 | MRG007 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders | CDH17 antagonists TOP1 inhibitors | Shanghai Miracogen, Inc. | Lepu Biopharma Co., Ltd. Arrivent BioPharma, Inc. Shanghai Miracogen, Inc. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | Exatecan | - | MRG007 | IgG1 - nd | - | detail > | |
| LBL-054-ADC | LBL-054-ADC | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders | CDH17 antagonists TOP1 inhibitors | Nanjing Leads Biolabs Co., Ltd. | Nanjing Leads Biolabs Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | Exatecan | - | LBL-054-ADC | IgG1 - nd | - | detail > | |
| LM-350 | LM-350 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | CDH17 antagonists TOP1 inhibitors | LaNova Medicines Ltd. | LaNova Medicines Ltd. | Phase 1/2 | IND Approval | - | - | - | - | - | Cleavable linker | - | 8 | LM-350 | - | - | detail > |
Total 60 data
1
2
3
4
5
6
